InxMed Signs a Clinical Trial Collaboration with Merck & Co for Patients with Pancreatic Cancer

 InxMed Signs a Clinical Trial Collaboration with Merck & Co for Patients with Pancreatic Cancer

Merck’s Gardasil 9 Receives FDA’s Expanded Label Approval for Prevention of HPV Related Disorders

Shots:

  • InxMed to sponsor the trial while Merck & Co (MSD outside the United States and Canada) will provide pembrolizumab for evaluation in the trial  
  • The focus of the collaboration is to evaluate the combination of InxMed’s IN10018 plus Merck’s pembrolizumab in patients with pancreatic cancer
  • IN10018 (formerly BI853520) is an investigational selective ATP-competitive focal adhesion kinase (FAK) inhibitor is under clinical development in the US and China and has shown safety & efficacy results against tumors. Keytruda (pembrolizumab) is an anti-PD-1 therapy that blocks interaction between PD-1 and its ligands

Click here to read full press release/ article | Ref: Globenewswire | Image: Twitter

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post